Somatropin biosimilar - USV

Drug Profile

Somatropin biosimilar - USV

Alternative Names: Human growth hormone biosimilar - USV

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator USV
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Somatotropin deficiency

Most Recent Events

  • 04 Sep 2017 Somatotropin biosimilar is still registered for Somatotropin deficiency (In children) in India (USV pipeline, August 2017)
  • 12 May 2015 USV has patent protection for somatropin biosimilar in USA and European Union (USV product pipeline, May 2015)
  • 16 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top